Lynx Investment Advisory’s GSK GSK Stock Holding History

Lynx Investment Advisory’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-116	Closed	-$4.46K	–	380
2024 Q2	$4.46K	Buy	+116	New	+$4.88K	﹤0.01%	481

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lynx Investment Advisory's GSK Position: Q3 2024 in Review

Lynx Investment Advisory sold out of GSK (GSK) in Q3 2024, closing a stake of 116 shares — an estimated $4.46K sold.

Lynx Investment Advisory first reported a position in GSK in Q2 2024 and held it in 1 quarter. The position peaked at $4.46K in Q2 2024. 899 funds tracked by Wall St. Rank hold GSK as of Q3 2024.

Lynx Investment Advisory reported no remaining GSK position as of Q3 2024 after selling out during the quarter.
Lynx Investment Advisory sold 116 GSK shares in Q3 2024, an estimated $4.46K.
Lynx Investment Advisory first reported a position in GSK in Q2 2024 and held it in 1 quarter.
Lynx Investment Advisory's GSK position peaked at $4.46K in Q2 2024.
899 funds tracked by Wall St. Rank held GSK as of Q3 2024.

Based on Lynx Investment Advisory's 13F filing for Q3 2024, filed 4 Nov 2024.